Last reviewed · How we verify
28 days treatment with Mifepristone.
At a glance
| Generic name | 28 days treatment with Mifepristone. |
|---|---|
| Also known as | Korlym, RU486 |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone (NA)
- Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. (PHASE3)
- Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer (PHASE1)
- Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 28 days treatment with Mifepristone. CI brief — competitive landscape report
- 28 days treatment with Mifepristone. updates RSS · CI watch RSS
- Stanford University portfolio CI